Karl Cahill
Gründer bei MOSS GENOMICS INC.
Vermögen: 76 500 $ am 30.04.2024
Profil
Karl Cahill is the founder and current Chief Executive Officer & Director of Moss Genomics, Inc., which is founded in 2018.
He was previously the Vice President-Investor Relations at Concordia Resource Corp.
from 2011 to 2012, and held the position of Head-Investor Relations at Raptor Pharmaceuticals Corp.
and Vice President-Investor Relations at AbraSilver Resource Corp.
Mr. Cahill completed his undergraduate degree at the University of Westminster.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
MOSS GENOMICS, INC.
5,70% | 22.02.2023 | 2 550 000 ( 5,70% ) | 76 500 $ | 30.04.2024 |
Aktive Positionen von Karl Cahill
Unternehmen | Position | Beginn |
---|---|---|
MOSS GENOMICS INC. | Gründer | 25.09.2018 |
Ehemalige bekannte Positionen von Karl Cahill
Unternehmen | Position | Ende |
---|---|---|
Concordia Resource Corp.
Concordia Resource Corp. Other Metals/MineralsNon-Energy Minerals Concordia Resource Corp. is a junior exploration company with an emphasis on developing mineral deposits in Africa and South America. The company has an extensive exploration portfolio in the resource-endowed regions of Burkina Faso, Gabon, and the Democratic Republic of Congo. In addition, it holds interests in the La Providencia silver mine located in the Puna district of northwestern Argentina and also holds interests in the Cerro Amarillo-Cajon Grande copper-gold-molybdenum property located in the Malargüe District of Argentina. The company was founded on February 7, 2000 and is headquartered in Vancouver, Canada. | Investor Relations Kontakt | 16.08.2012 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Public Communications Contact | 01.10.2009 |
ABRASILVER RESOURCE CORP. | Investor Relations Kontakt | - |
Ausbildung von Karl Cahill
University of Westminster | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ABRASILVER RESOURCE CORP. | Non-Energy Minerals |
MOSS GENOMICS INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
Concordia Resource Corp.
Concordia Resource Corp. Other Metals/MineralsNon-Energy Minerals Concordia Resource Corp. is a junior exploration company with an emphasis on developing mineral deposits in Africa and South America. The company has an extensive exploration portfolio in the resource-endowed regions of Burkina Faso, Gabon, and the Democratic Republic of Congo. In addition, it holds interests in the La Providencia silver mine located in the Puna district of northwestern Argentina and also holds interests in the Cerro Amarillo-Cajon Grande copper-gold-molybdenum property located in the Malargüe District of Argentina. The company was founded on February 7, 2000 and is headquartered in Vancouver, Canada. | Non-Energy Minerals |